Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway

Cancer Letters

Volumn 339, Issue 1, 2013, Pages 82-92

  Goudarzi, Houman ^a   Iizasa, Hisashi ^a   Furuhashi, Masako ^a   Nakazawa, Seitaro ^a   Nakane, Rie ^a   Liang, Shanshan ^a   Hida, Yasuhiro ^b   Yanagihara, Kazuyoshi ^c   Kubo, Takanori ^d   Nakagawa, Koji ^a   Kobayashi, Masanobu ^e   Irimura, Tatsuro ^f   Hamada, Jun ichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d YASUDA WOMEN'S UNIVERSITY   (Japan)

^e HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

HIF; Hypoxia; Invasiveness; Mesothelioma; Motility; MUC1

Indexed keywords

MUCIN 1;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL HYPOXIA; CELL MOTILITY; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSACTIVATION; TUMOR INVASION;

HIF; HYPOXIA; INVASIVENESS; MESOTHELIOMA; MOTILITY; MUC1;

CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MESOTHELIOMA; MUCIN-1; NEOPLASM INVASIVENESS; PLEURAL NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84883444953     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.020     Document Type: Article

References (48)

1. Zucali P.A., Giaccone G. Biology and management of malignant pleural mesothelioma. Eur. J. Cancer 2006, 42:2706-2714.
2. McDonald J.C. Health implications of environmental exposure to asbestos. Environ. Health Perspect. 1985, 62:319-328.
3. Aziz T., Jilaihawi A., Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10years. Eur. J. Cardiothorac. Surg. 2002, 22:298-305.
4. Semenza G.L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 2012, 18:534-543.
5. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Sem. Rad. Oncol. 2004, 14:198-206.
6. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
7. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
8. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
9. Ciborowski P., Finn O.J. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin. Exp. Metastasis 2002, 19:339-345.
10. Takeuchi H., Kato K., Denda-Nagai K., Hanisch F.G., Clausen H., Irimura T. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. J. Immunol. Methods 2002, 270:199-209.
11. Goudarzi H., Hida Y., Takano H., Teramae H., Iizasa H., Hamada J. Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma. Biomed. Res. 2013, 34:13-21.
12. Yanagihara K., Tsumuraya M., Takigahira M., Mihara K., Kubo T., Ohuchi K., Seyama T. An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int. J. Cancer 2010, 126:2835-2846.
13. Natsuizaka M., Ozasa M., Darmanin S., Miyamoto M., Kondo S., Kamada S., Shindoh M., Higashino F., Suhara W., Koide H., Aita K., Nakagawa K., Kondo T., Asaka M., Okada F., Kobayashi M. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp. Cell Res. 2007, 313:3337-3348.
14. Hamada J., Omatsu T., Okada F., Furuuchi K., Okubo Y., Takahashi Y., Tada M., Miyazaki Y.J., Taniguchi Y., Shirato H., Miyasaka K., Moriuchi T. Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. Int. J. Cancer 2001, 93:516-525.
15. Miyazaki Y.J., Hamada J., Tada M., Furuuchi K., Takahashi Y., Kondo S., Katoh H., Moriuchi T. HOXD3 enhances motility and invasiveness through the TGF-β-dependent and -independent pathways in A549 cells. Oncogene 2002, 21:798-808.
16. Wang G.L., Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 1993, 68:21513-21518.
17. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003, 63:6130-6134.
18. Carroll V.A., Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 2006, 66:6264-6270.
19. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
20. Yang M.H., Wu M.Z., Chiou S.H., Chen P.M., Chang S.Y., Liu C.J., Teng S.C., Wu K.J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10:295-305.
21. Sahlgren C., Gustafsson M.V., Jin S., Poellinger L., Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl. Acad. Sci. USA 2008, 105:6392-6397.
22. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 2010, 16:5928-5935.
23. Niizeki H., Kobayashi M., Horiuchi I., Akakura N., Chen J., Wang J., Hamada J.-I., Seth P., Katoh H., Watanabe H., Raz A., Hosokawa M. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br. J. Cancer 2002, 86:1914-1919.
24. Eguchi D., Ikenaga N., Ohuchida K., Kozono S., Cui L., Fujiwara K., Fujino M., Ohtsuka T., Mizumoto K., Tanaka M. Hypoxia enhances the interaction between pancreatic stellate cells and cancer cells via increased secretion of connective tissue growth factor. J. Surg. Res. 2013, 181:225-233.
25. Kimura H., Weisz A., Ogura T., Hitomi Y., Kurashima Y., Hashimoto K., D'Acquisto F., Makuuchi M., Esumi H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem. 2001, 276:2292-2298.
26. Harrison L., Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004, 9:31-40.
27. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 2005, 25:5675-5686.
28. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Res. Cancer 2012, 12:9-22.
29. Koh M.Y., Lemos R., Liu X., Powis G. The hypoxia-associated factor switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell, characteristics, aggressive tumor growth and invasion. Cancer Res. 2011, 71:4015-4027.
30. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 2003, 23:9361-9374.
31. Aubert S., Fauquette V., Hémon B., Lepoivre R., Briez N., Bernard D., Van Seuningen I., Leroy X., Perrais M. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009, 69:5707-5715.
32. Mikami Y., Hisatsune A., Tashiro T., Isohama Y., Katsuki H. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem. Biophys. Res. Commun. 2009, 379:1060-1065.
33. Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E.N., Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 1990, 265:15286-15293.
34. Litvinov S.V., Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J. Biol. Chem. 1993, 268:21364-21371.
35. Irimura T., Denda K., Iida S., Takeuchi H., Kato K. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity. J. Biochem. 1999, 126:975-985.
36. Ligtenberg M.J., Buijs F., Vos H.L., Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 1992, 52:2318-2324.
37. Kondo K., Kohno N., Yokoyama A., Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998, 58:2014-2019.
38. Suwa T., Hinoda Y., Makiguchi Y., Takahashi T., Itoh F., Adachi M., Hareyama M., Imai K. Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int. J. Cancer 1998, 76:377-382.
39. Satoh S., Hinoda Y., Hayashi T., Burdick M.D., Imai K., Hollingsworth M.A. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer 2000, 88:507-518.
40. Shen Q., Rahn J.J., Zhang J., Gunasekera N., Sun X., Shaw A.R., Hendzel M.J., Hoffman P., Bernier A., Hugh J.C. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol. Cancer Res. 2008, 6:555-567.
41. Roy L.D., Sahraei M., Subramani D.B., Besmer D., Nath S., Tinder T.L., Bajaj E., Shanmugam K., Lee Y.Y., Hwang S.I., Gendler S.J., Mukherjee P. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011, 30:1449-1459.
42. Bitler B.G., Goverdhan A., Schroeder J.A. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J. Cell Sci. 2010, 123:1716-1723.
43. Singh P.K., Wen Y., Swanson B.J., Shanmugam K., Kazlauskas A., Cerny R.L., Gendler S.J., Hollingsworth M.A. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res. 2007, 67:5201-5210.
44. Singh P.K., Behrens M.E., Eggers J.P., Cerny R.L., Bailey J.M., Shanmugam K., Gendler S.J., Bennett E.P., Hollingsworth M.A. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J. Biol. Chem. 2008, 283:26985-26995.
45. Wang Y., Roche O., Xu C., Moriyama E.H., Heir P., Chung J., Roos F.C., Chen Y., Finak G., Milosevic M., Wilson B.C., Teh B.T., Park M., Irwin M.S., Ohh M. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc. Natl. Acad. Sci. USA 2012, 109:4892-4897.
46. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer 1990, 61:924-926.
47. Destro A., Ceresoli G.L., Falleni M., Zucali P.A., Morenghi E., Bianchi P., Pellegrini C., Cordani N., Vaira V., Alloisio M., Rizzi A., Bosari S., Roncalli M. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215.
48. Chaika N.V., Gebregiworgis T., Lewallen M.E., Purohit V., Radhakrishnan P., Liu X., Zhang B., Mehla K., Brown R.B., Caffrey T., Yu F., Johnson K.R., Powers R., Hollingsworth M.A., Singh P.K. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2012, 109:13787-13792.